gefitinib has been researched along with agar in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (agar) | Trials (agar) | Recent Studies (post-2010) (agar) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 10,357 | 38 | 1,953 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianco, AR; Bianco, R; Caputo, R; Ciardiello, F; Damiano, V; De Placido, S; Fontanini, G; Melisi, D; Tortora, G; Veneziani, BM | 1 |
1 other study(ies) available for gefitinib and agar
| Article | Year |
|---|---|
Combination of a selective cyclooxygenase-2 inhibitor with epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 and protein kinase A antisense causes cooperative antitumor and antiangiogenic effect.
Topics: Agar; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Cell Line; Cyclic AMP-Dependent Protein Kinases; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; ErbB Receptors; Female; Gefitinib; Immunohistochemistry; Isoenzymes; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Oligonucleotides, Antisense; Prostaglandin-Endoperoxide Synthases; Protein-Tyrosine Kinases; Pyrazoles; Quinazolines; Sulfonamides | 2003 |